U.S. Markets closed

Select Medical valuation represents attractive entry point, says Susquehanna

Susquehanna believes Select Medical is on the cusp of implementing an aggressive growth/development program as Medicare reimbursement visibility improves. The firm sees current valuation as an attractive entry point for long-term investors citing its free cash flow yield and growth post-reimbursement visibility. Shares are Neutral rated with a $9 price target.